Direava

When you need broad, cross-specialty, enterprise-wide surgical video analytics immediately

• Vendors focused on enterprise-wide capture and analytics may provide broader cross-procedure coverage out of the box.

When connected-OR telepresence and remote expert collaboration are the primary requirements

• Vendors that specialize in remote collaboration and virtual scrub-in are generally a closer match for those needs.

When procurement requires public evidence of audited security certifications (SOC 2 / ISO 27001) and a mature trust center

• The company does not publicly document such certifications in the sources reviewed.

When the organization cannot support real-time integration effort

• Real-time intraoperative assistance typically requires dedicated video capture, low-latency processing, and OR display integration.

When independent, third-party user-review evidence is a procurement prerequisite

• The company lacks mainstream review-platform coverage in the public sources reviewed.

Limited public evidence base for procurement validation

• No substantial coverage on mainstream review platforms was identified; limited independent buyer feedback constrains assessment of usability, workflow fit, support quality, and ROI.

Narrow initial scope

• The regulated product appears to be indication- and system-specific in early releases, which may reduce immediate cross-service ROI compared with enterprise-focused vendors.

Security and compliance transparency gap

• Documentation of security certifications and enterprise security features was not found in public materials reviewed.

AI reliability and error disclosure

• Public materials reference efforts to reduce hallucination and error risk, but do not provide independent, rigorous error-rate disclosures for real-time decision-support deployments.

• Public company materials report manufacturing/marketing approval for a designated SaMD product in Japan dated December 9, 2025.

• The product is described as detecting specific structures (for example, nerves) in real time and indicating potential excessive traction as a safety cue.

• Company leadership and collaborations are publicly presented as closely linked to an academic medical center and government innovation programs.

• Many competing vendors emphasize retrospective analytics, OR efficiency, telepresence, or broad data-platform approaches. This company emphasizes intraoperative, real-time recognition in a defined clinical indication.

• No vendor or product listings were found on mainstream SaaS review platforms in the publicly accessible searches performed.

• No substantive discussions about the company were identified on Reddit or Hacker News in the searches performed.

• For early-stage, regulated medical products, public review-platform coverage is often limited; the closest public evidence is academic or clinical publications describing prototype or research work, and vendor-published case material.

• Regulatory milestone: the company reports a Japanese regulatory authorization for a designated SaMD product in late 2025.
• Clinical/academic engagement: the company reports an in-hospital demonstration of a surgical vision-language model at an academic medical center in early 2026; the demonstration materials are vendor-published and are not independently audited in the sources reviewed.

• Limited independent buyer feedback and mainstream review coverage makes it difficult to validate usability, workflow fit, reliability, support quality, and return on investment.
• Several public claims are vendor-published and are not supported by independent benchmarking in the sources reviewed.

• Ministry of Economy, Trade and Industry (METI) case material describes collaboration between Direava and an academic hospital on a vision-language AI aimed at intraoperative situational awareness and decision support. The public material notes that accuracy at the time of reporting was approaching a level useful for trainees, and that additional work is required before routine intraoperative reliance by attending surgeons.
• Direava press materials describe a real-time interactive surgical VLM demonstrated in a hospital setting and characterize the demonstration as meeting education-level criteria for anatomical accuracy and fluency. These demonstration results were vendor-published; methodology, sample size, error modes, and failure cases were not independently audited in the materials reviewed.
• An academic article documents AI-enhanced navigation in robotic hepatectomy with disclosures including equity ties between an author and Direava; this indicates potential conflicts of interest and links to company-sponsored research.

• A regulated, procedure-specific, real-time video-recognition Software as a Medical Device (SaMD) product referred to as "Kinosura".
• A broader surgical vision-language model (VLM) concept intended for real-time interpretation and interactive dialogue about intraoperative events; public descriptions characterize this as validated in an in-hospital demonstration or proof of concept rather than as a widely deployed commercial product.

• Surgeons, particularly those performing minimally invasive and robotic procedures
• Academic and teaching hospitals (use cases include education and quality/safety improvement)
• Hospital leadership focused on standardization and risk reduction

• Company materials identify clinical leadership within the founding team (the CEO is a practicing surgeon) and emphasize intraoperative support rather than retrospective analytics.